PMID- 23197874
OWN - NLM
STAT- MEDLINE
DCOM- 20130130
LR  - 20220129
IS  - 2157-6564 (Print)
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 1
IP  - 9
DP  - 2012 Sep
TI  - An abundant perivascular source of stem cells for bone tissue engineering.
PG  - 673-84
LID - 10.5966/sctm.2012-0053 [doi]
AB  - Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is 
      dispensable and accessible with minimal morbidity. However, the stromal vascular 
      fraction (SVF) of adipose tissue is a heterogeneous cell population, which has 
      disadvantages for tissue regeneration. In the present study, we prospectively 
      purified human perivascular stem cells (PSCs) from n = 60 samples of human 
      lipoaspirate and documented their frequency, viability, and variation with 
      patient demographics. PSCs are a fluorescence-activated cell sorting-sorted 
      population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells 
      (CD45-, CD146-, CD34+), each of which we have previously reported to have 
      properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF 
      from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These 
      numbers were minimally changed by age, gender, or body mass index of the patient 
      or by length of refrigerated storage time between liposuction and processing. In 
      a previous publication, we observed that human PSCs (hPSCs) formed significantly 
      more bone in vivo in comparison with unsorted human SVF (hSVF) in an 
      intramuscular implantation model. We now extend this finding to a bone injury 
      model, observing that purified hPSCs led to significantly greater healing of 
      mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 
      15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). 
      These studies suggest that adipose-derived hPSCs are a new cell source for future 
      efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based 
      therapeutic that is readily approvable by the U.S. Food and Drug Administration, 
      with potentially increased safety, purity, identity, potency, and efficacy.
FAU - James, Aaron W
AU  - James AW
AD  - Dental and Craniofacial Research Institute, UCLA, Los Angeles, CA, USA.
FAU - Zara, Janette N
AU  - Zara JN
FAU - Corselli, Mirko
AU  - Corselli M
FAU - Askarinam, Asal
AU  - Askarinam A
FAU - Zhou, Ann M
AU  - Zhou AM
FAU - Hourfar, Alireza
AU  - Hourfar A
FAU - Nguyen, Alan
AU  - Nguyen A
FAU - Megerdichian, Silva
AU  - Megerdichian S
FAU - Asatrian, Greg
AU  - Asatrian G
FAU - Pang, Shen
AU  - Pang S
FAU - Stoker, David
AU  - Stoker D
FAU - Zhang, Xinli
AU  - Zhang X
FAU - Wu, Benjamin
AU  - Wu B
FAU - Ting, Kang
AU  - Ting K
FAU - Peault, Bruno
AU  - Peault B
FAU - Soo, Chia
AU  - Soo C
LA  - eng
GR  - G1000816/MRC_/Medical Research Council/United Kingdom
GR  - T32 DE007296/DE/NIDCR NIH HHS/United States
GR  - 5T32DE007296-14/DE/NIDCR NIH HHS/United States
GR  - R21 DE0177711/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120905
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (Antigens, CD34)
RN  - 0 (CD146 Antigen)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Adipose Tissue/cytology
MH  - Adventitia
MH  - Animals
MH  - Antigens, CD34/analysis
MH  - *Bone Regeneration
MH  - *Bone and Bones
MH  - CD146 Antigen/analysis
MH  - Cell Separation
MH  - Humans
MH  - Leukocyte Common Antigens/analysis
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Mice
MH  - Pericytes
MH  - *Tissue Engineering
MH  - Tissue Scaffolds
MH  - Wound Healing
MH  - Wounds and Injuries/therapy
PMC - PMC3659737
EDAT- 2012/12/01 06:00
MHDA- 2013/01/31 06:00
PMCR- 2013/09/01
CRDT- 2012/12/01 06:00
PHST- 2012/12/01 06:00 [entrez]
PHST- 2012/12/01 06:00 [pubmed]
PHST- 2013/01/31 06:00 [medline]
PHST- 2013/09/01 00:00 [pmc-release]
AID - sctm.2012-0053 [pii]
AID - 3796005 [pii]
AID - 10.5966/sctm.2012-0053 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2012 Sep;1(9):673-84. doi: 10.5966/sctm.2012-0053. Epub 
      2012 Sep 5.